Boehringer and Ginkgo Ink Potential $400M+ Metagenomics Deal for “Undruggable” Targets
Boehringer and Ginkgo Ink Potential $400M+ Metagenomics Deal for “Undruggable” Targets (May 8, 2023) | By Inside Precision Medicine. Ginkgo Bioworks today announced a new partnership with Boehringer Ingelheim to
Biomica Announces Closing of $20 Million Financing Round led by Shanghai Healthcare Capital
Biomica Announces Closing of $20 Million Financing Round led by Shanghai Healthcare Capital (April 27, 2023) | By Biomica Ltd. REHOVOT, Israel, April 27, 2023 /PRNewswire/ — Biomica Ltd., a
Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies
Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies Financing will enable pivotal Phase 3 study of VE303 for recurrent C. difficile infection, to begin
DSM agrees terms to acquire postbiotics pioneer Adare Biome
DSM agrees terms to acquire postbiotics pioneer Adare Biome (April 19, 2023) | By Microbiome Times. Royal DSM, a global science-based leader in health, nutrition, and bioscience, announces that it
Ginkgo, hunting for biotech platforms that ‘collect dust,’ scoops up AAV gene therapy capsid specialist
Ginkgo, hunting for biotech platforms that ‘collect dust,’ scoops up AAV gene therapy capsid specialist (April 5, 2023) | By Annalee Armstrong. Ginkgo Bioworks doesn’t want the biotech industry’s therapies.
Covant Therapeutics Debuts with Boehringer Partnership Targeting ADAR1
Covant Therapeutics Debuts with Boehringer Partnership Targeting ADAR1 (March 29, 2023) | By Ana Mulero. Boston-based Covant Therapeutics gained $10 million upfront in a deal with Boehringer Ingelheim to chase
Bicycle, Novartis Ink Oncology Deal Worth up to $1.7B
Bicycle, Novartis Ink Oncology Deal Worth up to $1.7B (March 28, 2023) | By Rosemary Scott. Bicycle Therapeutics and Novartis announced Tuesday they have inked a deal worth up to $1.7 billion to discover and
With CTLA-4 Antibody Deal, BioNTech Comes Face-to-Face with BMS’ Yervoy
With CTLA-4 Antibody Deal, BioNTech Comes Face-to-Face with BMS’ Yervoy (March 21, 2023) | By Tristan Manalac. Monday, BioNTech inked an exclusive worldwide license and collaboration agreement with Maryland-based biopharma
CHARM Therapeutics Announces Collaboration with Bristol Myers Squibb to Enable and Accelerate Small Molecule Drug Discovery Programs
CHARM Therapeutics Announces Collaboration with Bristol Myers Squibb to Enable and Accelerate Small Molecule Drug Discovery Programs Collaboration will leverage CHARM’s DragonFold deep learning platform to identify compounds against targets
Pfizer’s $43B Seagen acquisition doubles early-stage oncology clinical pipeline
Pfizer’s $43B Seagen acquisition doubles early-stage oncology clinical pipeline Pfizer Inc. is set to acquire Seagen Inc. for $229 in cash per Seagen share for a total enterprise value of